6059-17-2

Usage

InChI:InChI=1/C9H11NO3/c1-2-13-9(12)7-4-3-6(10)5-8(7)11/h3-5,11H,2,10H2,1H3

Upstream product

• 78987-51-6 2-hydroxy-4-nitro-benzoic acid ethyl ester 
• 64-17-5 ethanol 
• 65-49-6 4-Aminosalicylic acid 
• 619-19-2 2-hydroxy-4-nitrobenzoic acid 
• 39614-82-9 2-hydroxy-4-nitrobenzoyl chloride 

Downstream Products

• 110462-20-9 2,2'-dihydroxy-4,4'-methanediyldiamino-di-benzoic acid diethyl ester 
• 91193-67-8 4-(2,2-dichloro-acetylamino)-2-hydroxy-benzoic acid ethyl ester 
• 860510-11-8 2-hydroxy-4-(2-hydroxy-4-nitro-benzoylamino)-benzoic acid ethyl ester 
• 32477-12-6 2-hydroxy-4-nicotinoylamino-benzoic acid ethyl ester 
• 6946-29-8 4-aminosalicylic acid hydrazide 
• 730977-57-8 ethyl 2-hydroxy-4-iodobenzoate 
• 84313-71-3 4-ethoxycarbonylamino-2-hydroxy-benzoic acid ethyl ester 
• 121970-39-6 2-hydroxy-4-[N'-(tri-O-acetyl-2-acetylamino-2-deoxy-β-D-glucopyranosyl)-thioureido]-benzoic acid ethyl ester 
• 79340-64-0 4-(2,7-Dimethyl-quinolin-4-ylamino)-2-hydroxy-benzoic acid ethyl ester; hydrochloride 
• 79340-66-2 4-(2,6-Dimethyl-quinolin-4-ylamino)-2-hydroxy-benzoic acid ethyl ester; hydrochloride 
• 79340-73-1 4-(7-Chloro-2-methyl-quinolin-4-ylamino)-2-hydroxy-benzoic acid ethyl ester; hydrochloride 
• 79358-79-5 4-(2,8-Dimethyl-quinolin-4-ylamino)-2-hydroxy-benzoic acid ethyl ester; hydrochloride 
• 79340-68-4 2-Hydroxy-4-(7-methoxy-2-methyl-quinolin-4-ylamino)-benzoic acid ethyl ester; hydrochloride 
• 79340-74-2 4-(6-Ethoxy-2-methyl-quinolin-4-ylamino)-2-hydroxy-benzoic acid ethyl ester; hydrochloride 

Relevant academic research and scientific papers

Synthesis and anti-mycobacterial activity of 4-(4-phenyl-1H-1,2,3-triazol-1-yl)salicylhydrazones: revitalizing an old drug

The antitubercular drug; para-aminosalicylic acid (PAS) was used as the core scaffold for the design of a series of 1H-1,2,3-triazolylsalicylhydrazones upon coupling with triazole and arylhydrazone moietis to furnish a single molecular architecture. The o

Fluoroquinolone derivative of p-aminosalicylic acid as well as intermediate, preparation method and application of fluoroquinolone derivative

The invention discloses a fluoroquinolone derivative of p-aminosalicylic acid as well as an intermediate, a preparation method and application of the fluoroquinolone derivative, and belongs to the technical field of drug synthesis. The structural formula of the fluoroquinolone derivative of p-aminosalicylic acid is shown in the specification. An in-vitro antibacterial activity determination resultshows that the target compound has good inhibition activity on bacteria as a whole; most compounds have good antibacterial activity on pichia pastoris, and some compounds have activity even strongerthan that of positive control drugs; the inhibitory activity of the two intermediates on mycobacterium smegmatis is higher than that of most positive control drugs; part of the target compounds have inhibitory activity on citrus germs. The fluoroquinolone derivative of p-aminosalicylic acid and the intermediate have potential application prospects in the fields of bacterium resistance, fungus resistance, tuberculosis resistance and citrus pathogen resistance.

P-aminosalicylic acid fluoroquinolone derivative as well as intermediate, preparation method and application thereof

The invention discloses a p-aminosalicylic acid fluoroquinolone derivative and an intermediate, a preparation method and application thereof, and belongs to the technical field of drug synthesis. Thestructural formula of the p-aminosalicylic acid fluoroquinolone derivative is shown in the specification. In-vitro activity determination results show that part of fluoroquinolone aminosalicylate derivatives (compounds for short) and intermediates have inhibition effects on mycobacterium smegmatis; the compounds and intermediates have good inhibition activity on common pathogenic bacteria as a whole; most compounds and intermediates have better antibacterial activity on pichia pastoris as a whole; part of the compounds have good inhibitory activity on citrus canker pathogens. The p-aminosalicylic acid fluoroquinolone derivative and the intermediate thereof have potential application prospects in the fields of tuberculosis resistance, bacteria resistance, fungus resistance and citrus pathogen resistance.

para-aminosalicylic acid azole derivative as well as preparation method and application thereof

The invention discloses a para-aminosalicylic acid azole derivative as well as a preparation method and application thereof, and belongs to the technical field of drug synthesis. The structural formula of the para-aminosalicylic acid azole derivative is shown in the specifications. An antibacterial activity determination result shows that the para-aminosalicylic acid azole derivative disclosed bythe invention has good inhibition activity on common pathogenic bacteria as a whole, and the antibacterial activity of part of molecules on pichia pastoris is stronger than or equal to that of a positive drug, fluconazole; all the molecules have good inhibitory activity on colletotrichum gloeosporioides, part of the molecules have the inhibitory activity equal to or higher than that of positive control prochloraz, and most of the molecules have a good inhibitory effect on citrus canker pathogens. An anti-tumor cell activity determination result shows that the para-aminosalicylic acid azole derivative disclosed by the invention has an inhibition effect on the three kinds of tumor cells. The para-aminosalicylic acid azole derivative disclosed by the invention has a potential application prospect in the fields of bacterium resistance, fungus resistance, citrus pathogen resistance and tumor resistance.

P-aminosalicylic acid dihydroartemisinin derivative as well as preparation method and application thereof

The invention discloses a p-aminosalicylic acid dihydroartemisinin derivative as well as a preparation method and application thereof, and belongs to the technical field of drug synthesis. The structural formula of the p-aminosalicylic acid dihydroartemis

Targeted Drug Delivery in Covalent Organic Nanosheets (CONs) via Sequential Postsynthetic Modification

Covalent organic nanosheets (CONs) have emerged as a new class of functional two-dimensional (2D) porous organic polymeric materials with a high accessible surface, diverse functionality, and chemical stability. They could become versatile candidates for targeted drug delivery. Despite their many advantages, there are limitations to their use for target specific drug delivery. We anticipated that these drawbacks could be overturned by judicious postsynthetic modification steps to use CONs for targeted drug delivery. The postsynthetic modification would not only produce the desired functionality, it would also help to exfoliate to CONs as well. In order to meet this requirement, we have developed a facile, salt-mediated synthesis of covalent organic frameworks (COFs) in the presence of p-toluenesulfonic acid (PTSA). The COFs were subjected to sequential postsynthetic modifications to yield functionalized targeted CONs for targeted delivery of 5-fluorouracil to breast cancer cells. This postsynthetic modification resulted in simultaneous chemical delamination and functionalization to targeted CONs. Targeted CONs showed sustained release of the drug to the cancer cells through receptor-mediated endocytosis, which led to cancer cell death via apoptosis. Considering the easy and facile COF synthesis, functionality based postsynthetic modifications, and chemical delamination to CONs for potential advantageous targeted drug delivery, this process can have a significant impact in biomedical applications.

Salicylic-acid derivatives as antennae for ratiometric luminescent probes based on lanthanide complexes

Long-lived ratiometric sensors: Luminescent lanthanide complexes are widely used in time-resolved assays of biomolecules, but most of the sensors with these complexes rely on single-point intensity measurements. Herein, we introduce a simple strategy to create ratiometric probes by using salicylic-acid derivatives as the antenna moiety of Tb3+ complexes. As an example, a probe for alkaline phosphatase (ALP) was developed (see scheme). Copyright

Benzoic acid derivatives and use thereof

A pharmaceutical composition for use in the treatment of psoriasis comprises 4-aminosalicylic acid (4-ASA) or 5-aminosalicylic acid (5-ASA) or a functional derivative thereof, said pharmaceutical composition being in a form suitable for topical administration. Furthermore, 4- or 5-ASA or a functional derivative thereof are used for the manufacture of pharmaceutical compositions for treating psoriasis, atopic dermatitis, allergic dermatitis, contact dermatitis, seborrhoic dermatitis, or acne diseases. The derivatives have the formulae: STR1 where W is COOX, wherein X is H, Li, Na, K, Mg0.5, Ca0.5, Zn0.5, Al0.33, Fe(II)0.5, Fe(III)0.33, NH4, NH3 R1, NH2 R12, NHR13, NR14, or R1, where R1 is substituted or unsubstituted C1-6 -alkyl, aryl-C1-4 -alkyl, or heteroaryl-C1-4 -alkyl; or COX, where X is NR1 R1', where R1' has the same meaning as R1 defined above and R1 and R1' may be identical or different; Y is H or R1 CO, where R1 is defined as above; Z1 and Z2, which may be identical or non-identical are H, R1 or R1 CO, where R1 is defined as above, or Z1 and Z2 represent R2, where R2 is substituted or unsubstituted C1-6 -alkylidene or aryl-C1-6 -alkylidene, or heteroaryl-C1-6 -alkylidene, or Z1, Z2 together with the nitrogen atom to which they are attached may represent a 3 to 7 membered saturated or unsaturated heterocyclic ring, or may represent a group of the formula --N=N--R3 where R3 is substituted or unsubstituted aryl or substituted or unsubstituted heteroaryl.